KRTAP2 Activators
KRTAP2 activators encompass a sophisticated group of chemicals that play a pivotal role in modulating the activity of KRTAP2, a protein with diverse functions in cellular processes. These activators exert their effects through indirect means, primarily by inhibiting specific signaling pathways that regulate KRTAP2 expression and function. Erlotinib, a well-known EGFR inhibitor, emerges as a notable KRTAP2 activator by targeting the EGFR signaling pathway. By inhibiting EGFR, Erlotinib indirectly activates KRTAP2, preventing its downregulation and sustaining cellular processes influenced by KRTAP2 through modulation of the EGFR cascade.
Sorafenib, a multi-kinase inhibitor, showcases the complexity of KRTAP2 regulation by targeting multiple signaling pathways, including RAF and VEGFR. GDC-0941, Dasatinib, Trametinib, and Wortmannin highlight the versatility of KRTAP2 activation by inhibiting the PI3K/AKT and Src signaling pathways. Afatinib and Saracatinib, both inhibitors of EGFR/HER2 and Src, respectively, contribute to sustained KRTAP2 activity, influencing cellular processes through modulation of their respective cascades. PI-103 and SB590885 further illustrate the diverse mechanisms through which KRTAP2 can be indirectly activated, focusing on the dual PI3K/mTOR and selective RAF pathways, respectively.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib, an EGFR inhibitor, indirectly activates KRTAP2 by suppressing the EGFR signaling pathway. By inhibiting EGFR, Erlotinib prevents KRTAP2 downregulation, fostering sustained KRTAP2 activity and influencing cellular processes through modulation of the EGFR cascade. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib, a dual EGFR/HER2 inhibitor, indirectly activates KRTAP2 by suppressing the EGFR/HER2 signaling pathway. This inhibition prevents KRTAP2 downregulation, fostering sustained KRTAP2 activity and influencing cellular processes through modulation of the EGFR/HER2 cascade. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a multi-kinase inhibitor, indirectly activates KRTAP2 by inhibiting multiple signaling pathways, including RAF and VEGFR. This inhibition prevents KRTAP2 downregulation, promoting sustained KRTAP2 activity and influencing cellular processes through modulation of various signaling cascades. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
GDC-0941, a PI3K inhibitor, indirectly activates KRTAP2 by suppressing the PI3K/AKT pathway. This inhibition prevents KRTAP2 downregulation, promoting sustained KRTAP2 activity. The compound influences cellular processes related to KRTAP2 through modulation of the PI3K/AKT signaling pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a Src family kinase inhibitor, indirectly activates KRTAP2 by suppressing the Src signaling pathway. This inhibition prevents KRTAP2 downregulation, fostering sustained KRTAP2 activity and influencing cellular processes through modulation of the Src signaling cascade. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, a MEK inhibitor, indirectly activates KRTAP2 by inhibiting the MAPK/ERK pathway. This inhibition prevents KRTAP2 downregulation, promoting sustained KRTAP2 activity. The compound influences cellular processes related to KRTAP2 through modulation of the MAPK/ERK signaling cascade. | ||||||
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $114.00 $198.00 | 13 | |
Afatinib, an irreversible EGFR/HER2 inhibitor, indirectly activates KRTAP2 by suppressing the EGFR/HER2 signaling pathway. This inhibition prevents KRTAP2 downregulation, fostering sustained KRTAP2 activity and influencing cellular processes through modulation of the EGFR/HER2 cascade. | ||||||
Saracatinib | 379231-04-6 | sc-364607 sc-364607A | 10 mg 200 mg | $115.00 $1056.00 | 7 | |
Saracatinib, a Src inhibitor, indirectly activates KRTAP2 by suppressing the Src signaling pathway. This inhibition prevents KRTAP2 downregulation, fostering sustained KRTAP2 activity and influencing cellular processes through modulation of the Src signaling cascade. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103, a dual PI3K/mTOR inhibitor, indirectly activates KRTAP2 by suppressing the PI3K/AKT/mTOR pathway. This inhibition prevents KRTAP2 downregulation, promoting sustained KRTAP2 activity. The compound influences cellular processes related to KRTAP2 through modulation of the PI3K/AKT/mTOR signaling pathway. | ||||||
SB 590885 | 405554-55-4 | sc-363287 sc-363287A | 10 mg 50 mg | $223.00 $942.00 | ||
SB590885, a selective RAF inhibitor, indirectly activates KRTAP2 by inhibiting the RAF/MEK/ERK pathway. This inhibition prevents KRTAP2 downregulation, promoting sustained KRTAP2 activity. The compound influences cellular processes related to KRTAP2 through modulation of the RAF/MEK/ERK signaling cascade. | ||||||